
Mylan launches generic version of Gilead’s remdesivir for COVID-19 patients in India
pharmafile | July 20, 2020 | News story | Sales and Marketing | COVID-19, Gilead, India, Mylan, generic, remdesivir
Mylan has launched its own generic version of Gilead’s remdesivir on the Indian market for the treatment of patients with COVID-19 under the brand name Desrem, it has emerged.
The therapy is priced at Rs 4,800, or $64, for a 100mg vial.
The antiviral therapy has generated a lot of attention in recent months for Gilead after showing promising efficacy across a number of studies in the treatment of patients hospitalised with COVID-19.
Under the terms of an agreement signed between the two companies, Mylan will exercise its right to commercialise remdesivir in the country, producing the drug at its injectable facility in Bengaluru. The first batch of the therapy has already been released, with future supply being ramped up by Mylan to meet increasing demand.
Other generic versions of remdesivir have already hit the Indian market from firms Hetero and Cipla after they also secured non-exclusive marketing rights to the therapy from Gilead in May.
Matt Fellows
Related Content

Gilead’s HIV treatment meets primary trial endpoint
Gilead has announced positive topline results from its phase 3 ARTISTRY-2 trial, which evaluated a …

Gilead announces first shipments of HIV prevention drug to Eswatini and Zambia
Gilead has announced the first shipments of its HIV prevention drug lenacapavir to Eswatini and …

COVID-19 vaccine eligibility creates challenges for UK pharmacies
Pharmacists across England have reported widespread confusion among patients attempting to book COVID-19 vaccination appointments …






